SALT LAKE CITY, April 28 /PRNewswire-FirstCall/ -- IOMED, Inc. today announced the appointment of Mr. James D. Isaacson as Director of Design and Development Engineering.
Mr. Isaacson has 19 years of experience as a product design engineer, with 16 years designing products specifically for medical applications. Mr. Isaacson has relevant experience managing engineers in a product development capacity with a strong background in project management and design controls. He spent almost a decade with Draper, Utah-based MegaDyne Medical Products, Inc., a manufacturer of reusable and disposable electrosurgical accessories. He held numerous engineering positions at MegaDyne, most recently as Director of Clinical Technologies. Before MegaDyne, Mr. Isaacson was with Cardiopulmonics, Inc, a Salt Lake City-based manufacturer of intravascular oxygenators, and with Cobe Laboratories, Inc. of Arvada, Colorado, a manufacturer of cardiovascular equipment for use in open heart surgery. He is the co-inventor of 13 U.S. patents. Mr. Isaacson received a M.S. in Mechanical Engineering from Massachusetts Institute of Technology and a B.S. in Mechanical Engineering from University of Michigan.
At IOMED, Mr. Isaacson will be responsible for design, development and the technology transfer of drug delivery products and other medical devices that fit within the Company's target markets. He will oversee product development from concept through the development cycle, and manage the strategic and technical direction to the project team.
"We are very pleased to welcome Jim to IOMED," said Mr. Robert J. Lollini, President and CEO. "His long and successful career in designing and developing specialty medical products fits well with our product development objectives. He is a top technical specialist in his field, with a strong grasp of clinical and scientific issues associated with medical products and their applications. We look forward to his contribution to IOMED and to the future expansion of our product line."
IOMED is a leader in developing, manufacturing and marketing active drug delivery systems used primarily to treat acute local inflammation in the physical and occupational therapy and sports medicine markets. The Company is pursuing opportunities to advance its position as a provider of quality, innovative non-invasive drug delivery products that improve patient healthcare. IOMED seeks to accomplish this by expanding its product line, distributing new products, developing strategic partnerships and acquisitions.
The statements contained in this news release that are not purely historical are forward-looking statements, as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and include IOMED's beliefs, expectations or intentions regarding its future operations and financial condition. All forward-looking statements included in this news release are made as of the date hereof and are based upon information available to IOMED as of such date. IOMED assumes no obligation to update any forward-looking statement. It is important to note that actual outcomes could differ materially from those in such forward-looking statements. Readers should also refer to the risk factors and other disclosures set forth in IOMED's filings with the Securities Exchange Commission on Form 10-K for its fiscal year ended June 30, 2003.
IOMED, Inc.CONTACT: Robert Lollini, President & CEO, +1-801-975-1191, or BetsyTruax, Corporate Communications, +1-801-975-1191, ext. 411, info@iomed.com,both of IOMED, Inc.
Web site: http://www.iomed.com/